Lixivaptan
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypervolemic Hyponatremia
Conditions
Hypervolemic Hyponatremia
Trial Timeline
Jul 1, 2009 → Dec 1, 2010
NCT ID
NCT00876876About Lixivaptan
Lixivaptan is a phase 3 stage product being developed by Biogen for Hypervolemic Hyponatremia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00876876. Target conditions include Hypervolemic Hyponatremia.
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00876876 | Phase 3 | Withdrawn |